Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889332 | 0.94 | FAAH (0.44) | MTNR1AMTNR1BMAPTACHECA1 | |
| SCHEMBL9218363 | 0.94 | FAAH (0.44) | MTNR1AMTNR1BMAPTACHECA1 | |
| SCHEMBL5859196 | 0.87 | KMT2A (0.48) | MAPTACHEALDH1A1KMT2AKDM4E | |
| SCHEMBL346094 | 0.85 | CA1 (0.53) | MTNR1AMTNR1BMAPTACHECA1 | |
| SCHEMBL7919875 | 0.84 | MTNR1A (0.43) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL345462 | 0.84 | MTNR1A (0.43) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8074296 | 0.84 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL545767 | 0.84 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL29958397 | 0.84 | MAPT (0.43) | MTNR1AMTNR1BMAPTACHECA1 | |
| SCHEMBL8606735 | 0.84 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MTNR1A 2205/4885MTNR1B 2787/4885MAPT 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.